Study control, violators, inclusion criteria and defining explanatory and pragmatic trials

被引:55
|
作者
McMahon, AD [1 ]
机构
[1] Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland
关键词
randomized controlled trial; pragmatic trial; explanatory trial; inclusion criteria; representativeness; intention to treat;
D O I
10.1002/sim.1120
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Important differences between explanatory and pragmatic studies were originally argued by Schwartz and Lellouch. Three important differences between the two types of study involve study control, study violators and inclusion criteria. It was originally argued that explanatory studies are highly controlled, and pragmatic studies may be looser and more like 'real life'. It was argued that an explanatory study should only analyse those receiving treatment, and a pragmatic study would analyse all randomized patients. Explanatory trials are said to use homogeneous groups, and pragmatic studies have less selection (better generalizability). Some suggestions are put forward to update the original distinctions between these two attitudes for future study design. Poor study control is undesirable (but might be necessary) and should not be welcomed as pragmatic. The intention-to-treat strategy is now considered as standard for nearly all trials. Homogeneity is a red herring for studies in humans. Inclusion criteria should be minimized and they should not be used to justify claims of representativeness. Routine criticism of randomized controlled trials for being unrepresentative is unwarranted. We should accept that most trials in humans are 'explanatory'. The division line should be moved, so that pragmatic studies are in the domain of non-therapeutics and complex treatments. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:1365 / 1376
页数:12
相关论文
共 50 条
  • [11] Making trials matter: pragmatic and explanatory trials and the problem of applicability
    Treweek, Shaun
    Zwarenstein, Merrick
    TRIALS, 2009, 10
  • [12] Making trials matter: pragmatic and explanatory trials and the problem of applicability
    Shaun Treweek
    Merrick Zwarenstein
    Trials, 10
  • [13] Explanatory versus pragmatic trials? The methods make the difference
    Merckx, Paul
    Paugam-Burtz, Catherine
    Boudinet, Sandrine
    Bonnet, Agnes
    Mantz, Jean
    ANESTHESIOLOGY, 2008, 108 (03) : 542 - 543
  • [14] Understanding explanatory and pragmatic trials: Examples from randomized controlled trials on vertebroplasty
    Eneling, J.
    Darsaut, T. E.
    Patel, M.
    Raymond, J.
    NEUROCHIRURGIE, 2023, 69 (01)
  • [15] Explanatory versus pragmatic trials? The methods make the difference - In reply
    Myles, Paul S.
    Leslie, Kate
    Chan, Matithew T. V.
    Forbes, Andrew
    Paech, Michael J.
    Peyton, Philip
    Silbert, Brendan S.
    Pascoe, Elaine
    ANESTHESIOLOGY, 2008, 108 (03) : 543 - 544
  • [16] The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials
    Vernon, Andrew
    Fielding, Katherine
    Savic, Rada
    Dodd, Lori
    Nahid, Payam
    PLOS MEDICINE, 2019, 16 (12)
  • [17] Applying pragmatic outcome criteria in clinical trials
    Kahn, R.
    EUROPEAN PSYCHIATRY, 2007, 22 : S12 - S12
  • [18] Modern trials are most useful when they are pragmatic and explanatory e there is no continuum
    Janiaud, Perrine
    Hemkens, Lars G.
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2024, 176
  • [19] Explanatory and pragmatic trials in orthopaedics - Have we done the right studies?
    Makaram, N. S.
    Simpson, A. Hamish R. W.
    INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 2023, 54
  • [20] Bridging the Gap Between Explanatory and Pragmatic Trials in Inflammatory Bowel Disease
    Roseira, Joana
    Jairath, Vipul
    INFLAMMATORY BOWEL DISEASES, 2025,